Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA

Key Points

• Deltec Asset Management cut its stake in Palvella by 80.8%, selling 10,100 shares and retaining 2,400 shares valued at about $251,000.
• Insider activity was mixed: Director Elaine J. Heron bought 2,400 shares at $125 (raising her holding to 47,812 shares) while COO Kathleen Goin sold 4,302 shares for roughly $507,593, and insiders now own 20.50% of the company.
• Analysts remain mostly positive—consensus rating "Moderate Buy" with an average price target of $198.07—despite Palvella missing quarterly EPS estimates and reporting negative earnings.

Deltec Asset Management LLC decreased its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 80.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,400 shares of the company's stock after selling 10,100 shares during the period. Deltec Asset Management LLC's holdings in Palvella Therapeutics were worth $251,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Archer Investment Corp acquired a new position in Palvella Therapeutics in the third quarter worth about $28,000. Bank of America Corp DE raised its position in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company's stock worth $294,000 after purchasing an additional 515 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter worth about $36,000. JPMorgan Chase & Co. raised its position in Palvella Therapeutics by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company's stock worth $272,000 after purchasing an additional 1,093 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics in the fourth quarter worth about $167,000. Institutional investors and hedge funds own 40.11% of the company's stock.

Insider Activity

In related news, Director Elaine J. Heron purchased 2,400 shares of the firm's stock in a transaction dated Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the director directly owned 47,812 shares of the company's stock, valued at $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The disclosure for this sale is available in the SEC filing. 20.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PVLA. Mizuho increased their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. BTIG Research increased their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Chardan Capital increased their price target on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. TD Cowen reissued a "buy" rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Palvella Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $198.07.

Palvella Therapeutics Price Performance

PVLA opened at $123.59 on Monday. Palvella Therapeutics, Inc. has a one year low of $20.20 and a one year high of $151.18. The company's 50 day simple moving average is $121.05 and its 200-day simple moving average is $99.86. The stock has a market capitalization of $1.77 billion, a P/E ratio of -33.31 and a beta of -0.21.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.13). As a group, analysts anticipate that Palvella Therapeutics, Inc. will post -4.87 EPS for the current year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.